Not that i have researched but hell yeah there are better alternatives the price its at and at that cheaper price we discussed..not sure dividends will b the same..
Anyone investing heavily this year??
- Thread starter rph2005
- Start date
Not that i have researched but hell yeah there are better alternatives the price its at and at that cheaper price we discussed..not sure dividends will b the same..
10 Most Shorted Stocks (Benziga Pro)
| Company | Ticker | Short % of Float |
| Venture Global | (NYSE:VG) | 80.57% |
| Avis Budget Group | (NASDAQ:CAR) | 57.06% |
| Choice Hotels International | (NYSE:CHH) | 55.87% |
| RH | (NYSE:RH) | 55.25% |
| Charter Communications | (NASDAQ:CHTR) | 50.40% |
| Lucid Group | (NASDAQ:LCID) | 42.84% |
| Ondas Holdings | (NASDAQ:ONDS) | 41.44% |
| CleanSpark | (NASDAQ:CLSK) | 40.30% |
| SoundHound AI | (NASDAQ:SOUN) | 39.89% |
| Bitdeer Technologies | (NASDAQ:BTDR) | 39.04% |
As a millennial I wear nothing but Nike but the younger generations are not locked in to the brand. They don't have any attachment. When I go to my gym, I rarely see any teens or people in their 20s wearing Nike. Thats not a good sign.
Bad part is i own soundhound..imma stick out for a minute and hopefully it makes it around the corner..
One positive for shorted stocks is that the right piece of news could cause a squeeze.
Who owns the press? What did Mr. Dr. Bledsoe say about the press?
Moderna stock soars 177%, Merck jumps 12% after cancer vaccine shows promise in late-stage trial
An experimental personalized cancer vaccine from Merck and Moderna showed positive initial results in its first-ever late-stage trial, the companies announced Wednesday, bringing them one step closer to filing for approval of the treatment option.
The mRNA-based shot in combination with Merck’s immunotherapy Keytruda met key goals in the Phase 3 trial in more than 1,100 patients with higher-risk or advanced melanoma whose detectable cancer had been completely removed through surgery.
Merck shares climbed more than 12% on Wednesday, while Moderna’s stock soared about 177%. The size of those moves reflect the companies’ relative size entering Wednesday: Merck’s market cap was around $333 billion, while Moderna’s sat near $25 billion.
The combination regimen met the main study goal of significantly extending the time patients lived without their melanoma returning, compared with Keytruda alone. The treatment also reduced the risk of the cancer spreading to distant parts of the body. Those results build on positive Phase 2 trial data on the same regimen earlier this year.
“It’s a big moment for medicine, a big moment for patients,” Moderna CEO Stephane Bancel said in an interview on CNBC’s “Squawk Box.”
The Phase 3 study will continue to assess other outcomes, including the overall survival benefit of the regimen. The drugmakers plan to present the data at an upcoming international medical meeting, but it’s unclear when they plan to submit applications for approval in the U.S.
The drugmakers will likely start talking to regulatory agencies about the treatment and its safety “in the next few months,” Dr. Dean Li, president of Merck Research Laboratories, told “Squawk Box.”
The initial data suggests that the combo could serve as a new treatment option for melanoma, which accounts for only about 1% of skin cancers but causes the large majority of deaths among them. Most recurrences of melanoma develop in the first two to three years after initial treatment and removal.
Melanoma patients are “stuck having to deal with the new gravity of that diagnosis and then undergo uncomfortable treatments like surgery, and after that, they’re worried about their cancer coming back,” Dr. Jane Healy, Merck’s head of oncology early development, said in an interview.
She called it “very exciting” that the therapy led to a “clinically meaningful improvement” over Keytruda – the standard of care for melanoma – and was well tolerated by patients. Side effects were similar to other vaccines that people typically get for other diseases, Healy noted.
The results also validate a personalized treatment approach that Merck and Moderna have been developing for decades, she added.
Every tumor has a unique set of mutations, even among patients with the same type of cancer, Healy said. Merck and Moderna’s personalized vaccine is designed to target the specific mutations in each patient’s tumor rather than using a one-size-fits-all approach. The idea is to train the immune system to recognize and kill those unique cancer markers and then pair that response with Keytruda, which helps the body attack the cancer more effectively.
“We think [the results are] very meaningful for patients with this disease and really the potential of what it can mean for other patients for cancer in future trials with this particular new class of therapy,” she said.
In a June note ahead of the results, Leerink Partners analyst Mani Foroohar said the Phase 3 results are a make-or-break event for Moderna’s stock.
Analysts said the company’s valuation already reflected expectations that the personalized cancer vaccine could eventually work across multiple types of cancers – not just melanoma — before Wednesday’s stock move.
Merck and Moderna are studying the vaccine in several trials across other tumors, such as non-small cell lung cancer, bladder cancer and renal cell carcinoma.
Cancer vaccine from Moderna, Merck shows promise in late-stage trial; both stocks soar
The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone.
Amazing.Moderna stock soars 177%, Merck jumps 12% after cancer vaccine shows promise in late-stage trial
An experimental personalized cancer vaccine from Merck and Moderna showed positive initial results in its first-ever late-stage trial, the companies announced Wednesday, bringing them one step closer to filing for approval of the treatment option.
The mRNA-based shot in combination with Merck’s immunotherapy Keytruda met key goals in the Phase 3 trial in more than 1,100 patients with higher-risk or advanced melanoma whose detectable cancer had been completely removed through surgery.
Merck shares climbed more than 12% on Wednesday, while Moderna’s stock soared about 177%. The size of those moves reflect the companies’ relative size entering Wednesday: Merck’s market cap was around $333 billion, while Moderna’s sat near $25 billion.
The combination regimen met the main study goal of significantly extending the time patients lived without their melanoma returning, compared with Keytruda alone. The treatment also reduced the risk of the cancer spreading to distant parts of the body. Those results build on positive Phase 2 trial data on the same regimen earlier this year.
“It’s a big moment for medicine, a big moment for patients,” Moderna CEO Stephane Bancel said in an interview on CNBC’s “Squawk Box.”
The Phase 3 study will continue to assess other outcomes, including the overall survival benefit of the regimen. The drugmakers plan to present the data at an upcoming international medical meeting, but it’s unclear when they plan to submit applications for approval in the U.S.
The drugmakers will likely start talking to regulatory agencies about the treatment and its safety “in the next few months,” Dr. Dean Li, president of Merck Research Laboratories, told “Squawk Box.”
The initial data suggests that the combo could serve as a new treatment option for melanoma, which accounts for only about 1% of skin cancers but causes the large majority of deaths among them. Most recurrences of melanoma develop in the first two to three years after initial treatment and removal.
Melanoma patients are “stuck having to deal with the new gravity of that diagnosis and then undergo uncomfortable treatments like surgery, and after that, they’re worried about their cancer coming back,” Dr. Jane Healy, Merck’s head of oncology early development, said in an interview.
She called it “very exciting” that the therapy led to a “clinically meaningful improvement” over Keytruda – the standard of care for melanoma – and was well tolerated by patients. Side effects were similar to other vaccines that people typically get for other diseases, Healy noted.
The results also validate a personalized treatment approach that Merck and Moderna have been developing for decades, she added.
Every tumor has a unique set of mutations, even among patients with the same type of cancer, Healy said. Merck and Moderna’s personalized vaccine is designed to target the specific mutations in each patient’s tumor rather than using a one-size-fits-all approach. The idea is to train the immune system to recognize and kill those unique cancer markers and then pair that response with Keytruda, which helps the body attack the cancer more effectively.
“We think [the results are] very meaningful for patients with this disease and really the potential of what it can mean for other patients for cancer in future trials with this particular new class of therapy,” she said.
In a June note ahead of the results, Leerink Partners analyst Mani Foroohar said the Phase 3 results are a make-or-break event for Moderna’s stock.
Analysts said the company’s valuation already reflected expectations that the personalized cancer vaccine could eventually work across multiple types of cancers – not just melanoma — before Wednesday’s stock move.
Merck and Moderna are studying the vaccine in several trials across other tumors, such as non-small cell lung cancer, bladder cancer and renal cell carcinoma.
Cancer vaccine from Moderna, Merck shows promise in late-stage trial; both stocks soar
The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone.www.cnbc.com
Ask the CEO those questions.
Have people realized that their shoes are overpriced and the quality isn’t that good when compared to brands like Hoka, Brooks, and others?
For anyone seeking exposure to Anthropic before its IPO, I searched Chatgpt and found a few ETFs that currently provide such exposure.
| ETF | Anthropic exposure | Structure | My take |
|---|---|---|---|
| LAZR | ~12.06%* | Anthropic via SPV | Highest exposure |
| ALAI | ~2.58% | Private holding | Broader AI portfolio |
| AGIX | ~1.92% currently | Direct private investment | Best public/private AI strategy |
Man I have several thoughts, but overall his comments were distasteful and he let his emotions get the best of him. I listened to his apology and further comments on Black Out, but I hope this is a learning lesson that in the future keep those thoughts to yourself or talk about your feelings in private.
We are all human and no one is perfect, so we make mistakes and I hope that he has learned a valuable lesson....
The thing I didn't understand is why are people calling them scammers???
Last edited:
I think in past when they were kind of getting started, the had some shady ppl on the roster. They were endorsing ppl without doing a thorough research about theses ppl, I remember jay Morrison and him500 was in the mix at one point. But once they found out about how shady some of them were they had to pivot and start doing more stuff themselves. They admitted they didn't do their research like they should have when this occurred. So some social media/influencers are holding on to that even tho they have distance themselves from those ppl.
Oh yeah that's right....
Hey fellas hear me out.....
I think it might (possibly) be time to consider rotating some of your investments into crypto pretty soon
Dollar cost averaging over the next few months
South Korea's market is in freefall
Japan is having issues with its economy & currency
Over here in the USA, this AI bubble might be running out of steam pretty soon
Tokenized assets & blockchain will more than likely be part of the future going forward
When the shit finally hits the fan, yall won't be able to buy any crypto
Because public exchanges (Coinbase, Finance, Gemini, Kraken) will probably be having database errors, like @HNIC is running it
This is what happened last year, October 2025
So you need to be at least somewhat positioned beforehand
Large financial institutions (like Blackrock & Fidelity, etc, etc) are buying from private brokers
So they won't have a problem.....but you will
Don't be too too greedy trying to squeeze every dollar, close to the top of this stock market bubble
"Bulls make money, Bears make money, Pigs get slaughtered"
Check out this youtube vid below, when y'all get a chance.....
^^^
Last edited:
Hundreds of customers report losses as North Vancouver currency exchange investigated for fraud
Hundreds of customers are demanding answers and their money after they claim a North Vancouver currency exchange stopped returning customer funds, prompting a fraud investigation by North Vancouver RCMP.
Few options for customers owed as much as $5 million by North Vancouver currency exchange
Unlike many other companies in the financial sector, money-services businesses are largely unregulated
The $1.5 Million Question: What Happened Inside Vancouver’s Apadana Currency Exchange?
On Sunday, August 16, local Persian-language media in British Columbia, Canada, widely reported the sudden “bankruptcy announcement” of ...
iranwire.com
Legal experts say customers may have limited options for recovering their money.
“This sort of falls into kind of a no man’s land. It’s not like a bank or a trust company or even an insurance company. We don’t really have any oversight, regulatory oversight, into the business,” said lawyer Jeffrey Simser.
Hundreds of customers report losses as North Vancouver currency exchange investigated for fraud
Hundreds of customers are demanding answers and their money after they claim a North Vancouver currency exchange stopped returning customer funds, prompting a fraud investigation by North Vancouver RCMP.www.ctvnews.ca
I forgot about that dude. Used to follow his YouTube.
Fuck Wu-tang! Allowing some rich guy to buy their last album and keep it to themself was the biggest fuck you to anyone who supported these niggas.
Bank of Canada concerned over private credit risks - National | Globalnews.ca
The Bank of Canada is carefully watching the rise of an alternative credit model that has Canadian investors and banks exposed to half a trillion dollars of loans.
globalnews.ca
OTTAWA – The Bank of Canada is carefully watching the rise of an alternative credit model that has Canadian investors and banks exposed to half a trillion dollars of loans held largely beyond the public eye.
The concern revolves around private credit, which doesn’t have a universal definition but broadly involves businesses taking out loans from non-bank lenders including asset managers, insurers and pension funds.
A mid-sized business might turn to private credit if they’re looking for money to fund the next stage of growth but are still too small for a traditional bank loan or issuing debt on the bond market.
Similar threads
